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Abstract
Increased endothelial permeability, one of the earliest signs of endothelial dysfunction, is associated with the
development of cardiovascular diseases such as hypertension and atherosclerosis. Recent studies suggest that the
receptor for advanced glycation end products (RAGE) regulates endothelial permeability in inﬂammation. In the
present study, we investigated the regulatory mechanism of RAGE in endothelial hyperpermeability induced by
angiotensin II (Ang II), a well-known inﬂammatory mediator, and the potential therapeutic effect of soluble RAGE
(sRAGE), a decoy receptor for RAGE ligands. For in vitro studies, Ang II-treated human umbilical vein endothelial cells
(HUVECs) were treated with siRNA speciﬁc to either RAGE or sRAGE to disrupt RAGE-mediated signaling. Endothelial
permeability was estimated using FITC-labeled dextran 40 and a resistance meter. To evaluate intercellular junction
disruption, VE-cadherin expression was examined by western blotting and immunocytochemistry. Ang II increased the
expression of the Ang II type 1 receptor (AT1R) and RAGE, and this increase was inhibited by sRAGE. sRAGE prevented
Ang II-induced VE-cadherin disruption in HUVECs. For in vivo studies, Ang II-infused, atherosclerosis-prone
apolipoprotein E knockout mice were utilized. Endothelial permeability was assessed by Evans blue staining of the
aorta. Ang II increased endothelial barrier permeability, and this effect was signiﬁcantly attenuated by sRAGE. Our data
demonstrate that blockade of RAGE signaling using sRAGE attenuates Ang II-induced endothelial barrier permeability
in vitro and in vivo and indicate the therapeutic potential of sRAGE in controlling vascular permeability under
pathological conditions.
Introduction
Endothelial cells play a critical role in maintaining the
homeostasis of blood vessels. Regulation of the endothe-
lial barrier is important for maintaining the integrity of
cell-to-cell adhesion because increased endothelial per-
meability can lead to endothelial dysfunction, a common
prelude to the development of vascular diseases such as
atherosclerosis1. Endothelial hyperpermeability is also a
signiﬁcant problem in a number of conditions, such as
vascular inﬂammation, ischemia–reperfusion injury, dia-
betes, and thrombosis and cancer2. Excessive inﬂamma-
tory stimuli, such as transforming growth factor-beta
(TGF-β), thrombin, and tumor necrosis factor-alpha
(TNF-α), can trigger actin cytoskeleton reorganization
via such events as ﬁlamentous actin (F-actin) disruption,
stress ﬁber formation, and cytoskeletal contraction, lead-
ing to transendothelial ﬂux via the widened intercellular
space2,3. Since reduced availability of nitric oxide due to
high oxidative stress and inﬂammation can also cause
endothelial hyperpermeability4,5, angiotensin II (Ang II)
can be another key modulator of endothelial hyperper-
meability, because the renin–angiotensin system (RAS)
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can lead to both high oxidative stress and inﬂammation,
causing abnormal NO metabolism6.
Ang II is an important vasoconstrictor in the RAS and
exerts multiple functional effects on endothelial cells,
including excessive oxidative stress, vascular inﬂamma-
tion, thrombosis, and remodeling of the actin cytoskele-
ton7. Although Ang II is known to induce endothelial
hyperpermeability8, and previous studies have shown that
Rac and Rho kinase mediate Ang II-induced cytoskeletal
remodeling9,10, the underlying mechanisms by which Ang
II induces endothelial hyperpermeability have not been
completely elucidated. The biological action of Ang II is
mainly mediated by the Ang II type 1 receptor (AT1R),
and recent studies have suggested a link between AT1R
and the receptor for advanced glycation end products
(RAGE) as an important signaling pathway in vascular
smooth muscle cells and podocytes11,12.
RAGE is a multiligand signal transduction receptor that
recognizes various endogenous ligands, such as high
mobility group box 1 (HMGB1), advanced glycation end
products (AGE), macrophage-1 antigen (Mac-1), and
S100/calgranulins, and plays an important role in indu-
cing inﬂammatory reactions through the activation of
protein kinase C (PKC)/phosphoinositide 3-kinase
(PI3K)/Akt, Janus kinase/signal transducer and activator
of transcription (JAK/STAT), mitogen-activated protein
kinase (MAPK), extracellular signal-regulated kinase
(ERK), and Src/RhoA/Cdc42, leading to the activation of
transcription factors such as NF-κB and Egr113. Regarding
the role of RAGE signaling in endothelial dysfunction,
studies showed that AGE increased endothelial perme-
ability through the RAGE/Rho signaling pathway or Src
phosphorylation in human umbilical vein endothelial cells
(HUVECs)14,15 and that AGE-induced Src phosphoryla-
tion and barrier dysfunction were inhibited in the pul-
monary microvascular endothelial cells of RAGE
knockout mice14.
Although these ﬁndings provide circumstantial evidence
of possible crosstalk between AT1R-mediated signaling
and RAGE-mediated signaling in Ang II-induced endo-
thelial hyperpermeability, this link has not been empiri-
cally examined, and the underlying mechanism remains
elusive. Therefore, in the present study, we investigated
the regulatory mechanism of RAGE in Ang II-induced
endothelial hyperpermeability and the potential ther-
apeutic effect of soluble RAGE (sRAGE), a decoy receptor
for RAGE ligands.
Materials and methods
Chemicals and antibodies
Puriﬁed human soluble RAGE-Fc fusion protein
(sRAGE) was purchased from Y-biologics (Daejeon,
Republic of Korea). Ang II, losartan, caffeic acid phenethyl
ester (CAPE), and ﬂuorescein isothiocyanate (FITC)-
labeled dextran 40 were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Puriﬁed anti-HMGB1 antibody (651402)
was purchased from BioLegend (San Diego, CA, USA).
Anti-AT1R antibody (AAR-011) was purchased from
Alomone Labs (Hadassah Ein Kerem, Israel). Anti-RAGE
(ab3611), anti-mDia1 (ab129167), and anti-HMGB1
(ab18256) antibodies were purchased from Abcam (Cam-
bridge, UK). Anti-Src (2109s), anti-phospho-Src (6943s,
Tyr416), anti-β-catenin (8480s), anti-phospho β-catenin
(5651s, Ser522), and anti-phospho-NF-κB (3033s, Ser536)
antibodies were obtained from Cell Signaling Technology
(Danvers, MA, USA). Anti-phospho-VE-cadherin (LS-
C357312, Tyr731) was purchased from LifeSpan Bios-
ciences (Seattle, WA, USA). Anti-VE-cadherin (sc9989),
anti-NF-κB (sc8008), anti-β-actin (sc47778), and anti-
GAPDH (sc32233) antibodies were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA).
Cell culture
HUVECs were purchased from Lonza and maintained
in endothelial growth medium-2 (EGM-2, Lonza, Basel,
Switzerland) supplemented with 2% (v/v) fetal bovine
serum (FBS) at 37 °C in a humidiﬁed atmosphere con-
taining 5% CO2. HUVECs were cultured in 1.5% gelatin-
coated cell culture dishes, and cells at passages 4–8 were
used in the experiments.
Permeability assay
HUVECs were grown in the upper chambers of 24-well
Transwell inserts (0.4 μm pore size; Corning, NY, USA)
until a conﬂuent monolayer was formed. For endothelial
permeability assays, HUVECs were starved in serum-free
EBM-2 for 3 h. After starvation, the upper and lower
chambers were pretreated with sRAGE for 1 h and then
with Ang II for 4 h. Subsequently, ﬂuorescein iso-
thiocyanate (FITC)-labeled dextran 40 (ﬁnal concentra-
tion of 10 mg/ml in basal medium) was added as a tracer
to the upper chamber, and cells were incubated for 1 h at
37 °C. After incubation, the medium in the lower chamber
was collected into a black 96-well plate, and ﬂuorescence
was measured with a ﬂuorescence plate reader (Varioskan
Flash; Thermo Fisher Scientiﬁc, Waltham, MA, USA) at
485 nm excitation and 530 nm emission wavelengths. The
permeability of the endothelial monolayer was evaluated
by calculating the permeability coefﬁcient of dextran by
the following formula: Pd= [A]/t × 1/A × V/[L], where [A]
is the dextran concentration in the bottom chamber, t is
the time in seconds, A is the area of the membrane (in
cm2), V is the volume of the bottom chamber, and [L] is
the dextran concentration in the upper chamber14.
Transendothelial electrical resistance
The transendothelial electrical resistance (TEER) of the
HUVEC monolayer was determined using an STX2
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electrode and EVOM2 meter (World Precision Instru-
ments, Sarasota, FL, USA) according to the manu-
facturer’s instructions. HUVECs were seeded in the upper
chambers of a 12-well Transwell insert (0.4 μm pore size)
and grown to conﬂuence. The resistance values of mul-
tiple Transwell inserts in each experimental group were
measured sequentially, and the mean was expressed in
common units (ohm cm2) after the value of a blank, cell-
free insert was subtracted. The values were normalized to
that of untreated control cells before stimulation.
Immunocytochemistry
HUVECs were plated in four-well glass chamber slides
and cultured to conﬂuence. After sequential treatment
with the indicated stimulant, cells were washed in
phosphate-buffered saline (PBS) three times, and were
then ﬁxed with 4% paraformaldehyde for 10min. Cells
were washed again with PBS, followed by blocking with
0.5% bovine serum albumin (BSA) at room temperature
and incubation with the appropriate mouse monoclonal
VE-cadherin antibody overnight at 4 °C. After three
washes with PBS, cells were incubated with FITC-
conjugated goat anti-mouse antibody at room tempera-
ture for 1 h in the dark. Cells were mounted using DAPI-
containing mounting medium (Santa Cruz Biotechnol-
ogy). Immunoreactivity signals were visualized by con-
focal laser scanning microscopy (LSM780; Carl Zeiss,
Dresden, Germany).
RNA interference
A TriFECTa DsiRNA Kit for Diaphanous-related for-
min-1 (mDia1) was purchased from IDT (Coralville, IA,
USA). Scrambled and RAGE siRNAs (siRNA no. 1003394)
were purchased from Bioneer (Daejeon, Republic of
Korea). Brieﬂy, cells at 60–80% conﬂuence were trans-
fected with 200 nM RAGE siRNA, scrambled siRNA
(negative control), or 20 nM mDia1 siRNA using RNAi-
Max (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. After 4 h of transfection, the
medium was exchanged with fresh medium.
Western blot analysis
HUVECs were lysed in RIPA buffer (Biosesang, Gye-
noggi-do, Republic of Korea) containing a mixture of
protease inhibitors (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) and centrifuged to extract total protein. Pro-
tein concentrations were determined using a BCA protein
assay kit (Sigma-Aldrich, St. Louis, MO, USA) according
to the manufacturer’s instructions, and 25 µg of protein
was analyzed by 8% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-
Rad, Hercules, CA, USA). Membranes with transferred
proteins were blocked with 5% skim milk (BD Biosciences,
San Jose, CA, USA) for 1 h and incubated overnight at
4 °C with antibodies against the following proteins: AT1R,
RAGE, mDia1, Src, phospho-Src, β-catenin, phospho-
β-catenin, VE-cadherin, phospho-VE-cadherin, HMGB1,
NF-κB, phospho-NF-κB, β-actin, and GAPDH. The rela-
tive intensities of protein bands were analyzed using
ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
Reverse transcription polymerase chain reaction
RNA was isolated from cells using a Ribospin kit
(GeneAll, Seoul, Republic of Korea) according to the
manufacturer’s instructions. Single-stranded com-
plementary DNA (cDNA) was synthesized from 1 μg of
total RNA with oligo-deoxythymidine (dT) primers using
reverse transcriptase (Bio-Rad). The RAGE primer set was
purchased from Bioneer (p202745). Additional primer
sets were purchased from IDT and validated. The fol-
lowing primer sequences were used: 5′-CAC CAT GTT
TTG AGG TTG AGT GAC-3′ and 5′-CAG GCT AGG
GAG ATT GCA TTT CTG-3′ for AT1R; 5′-GGG AGC
AAA TCC CAC CTT TA-3′ and 5′-GGT CAC AGT ACA
ACC CAT AGTC-3′ for mDia1; 5′-CGA CCA CTT TGT
CAA GCT CA-3′ and 5′-AGG GGA GAT TCA GTG
TGG TG-3′ for GAPDH; and 5′-ATT CCG ATA ACG
AAC GAG AC-3′ and 5′-GCT TAT GAC CCG CAC
TTA CT-3′ for 18S rRNA. The mean values from tripli-
cate (n= 3) measurements were used to calculate gene
expression after normalization to 18S rRNA levels as the
internal control.
Measurement of HMGB1
Culture medium was concentrated from 6 to 1ml using
a centrifugal ﬁlter device (Millipore, Billerica, USA). Then,
the HMGB1 levels in culture medium were determined by
using an ELISA kit (Chondrex, Redmond, WA, USA)
according to the manufacturer’s instructions and by
western blot analysis using 20 μl of culture medium.
In vivo study using apolipoprotein E knockout mice
Atherosclerosis-prone apolipoprotein E knockout
(ApoE KO) mice, a well-established model of experi-
mental atherosclerosis16,17, were used for in vivo studies.
Twelve-week-old male ApoE KO mice on a C57BL/6J
background were obtained from Jackson Laboratory (Bar
Harbor, ME, USA). The animals were housed in a room
with a 12-h light/dark cycle and were maintained in
temperature-controlled clean racks for 6 weeks. All ani-
mal studies and postmortem procedures were approved
by the Institutional Animal Care and Use Ethics Com-
mittee of Yonsei University (approval reference number:
2014-0350) in accordance with the NIH Guide for the
Care and Use of Laboratory Animals.
ApoE KO mice were divided into the following four
groups: the untreated control group [saline intraperitoneal
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(IP) injection], Ang II infusion group, Ang II infusion with
sRAGE IP injection group, and sRAGE IP injection group.
Animals were anaesthetized via IP injection of Zoletil
(30mg/kg) and Rompun (10mg/kg), and Alzet® osmotic
minipumps (model 2006; DURECT Corporation, Cuper-
tino, CA, USA) were implanted subcutaneously for the
infusion of Ang II at a dosage of 1.5 μg/kg/min for 42 days.
sRAGE was injected intraperitoneally daily for 42 days at a
dosage of 2 μg/mouse/day.
Evans blue administration and quantiﬁcation
Animals were perfused with 5% Evans blue dye in saline
through the jugular vein for 45min. Animals were anes-
thetized and perfused via the left ventricle with cold PBS,
and the aorta was removed. Aortas were measured and
quantiﬁed using ImageJ software. Evans blue dye was
eluted from the aortas by incubation with formamide at
56 °C for 2 days. The amount of dye was quantiﬁed by
spectrophotometry at 610 nm.
Transmission electron microscopy
To examine endothelial permeability, aortic tissues were
ﬁxed for 12 h in 2% glutaraldehyde–paraformaldehyde in
0.1M phosphate buffer (pH 7.4), washed in 0.1M phos-
phate buffer, and postﬁxed with 1% OsO4 dissolved in
0.1M phosphate buffer for 2 h. Then, samples were
dehydrated in ethanol and inﬁltrated with propylene
oxide. Specimens were embedded with a Poly/Bed 812 kit
(Polysciences), and 200–250-nm-thick sections were
initially cut and stained with toluidine blue (T3260;
Sigma-Aldrich, St. Louis, MO, USA) for light microscopy.
Ultrathin sections (70 nm) were cut by a LEICA EM UC-7
(Leica Microsystems, Vienna, Austria) with a diamond
knife (Diatome) and were double stained with 6% uranyl
acetate (22400; Electron Microscopy Sciences, Hatﬁeld,
PA, USA) for 20min and lead citrate (Thermo Scientiﬁc,
Waltham, MA, USA) for 10min. All sections were eval-
uated by transmission electron microscopy (TEM) (JEM-
1011; JEOL Ltd., Tokyo, Japan) at an acceleration voltage
of 80 kV.
Statistical analysis
ImageJ 10.0, SigmaPlot, and GraphPad Prism 5.01 were
used for data analysis and visualization. All data are
expressed as the means ± SEMs of at least three indepen-
dent experiments. Statistical comparisons were performed
using Student’s t-test or one-way analysis of variance
(ANOVA) with Tukey’s multiple comparisons test. P values
of less than 0.05 were considered statistically signiﬁcant.
Results
Ang II induced endothelial hyperpermeability in HUVECs
Ang II is known to induce endothelial hyperperme-
ability. According to our data, as the concentration of Ang
II (100, 300, 500, and 1000 nM for 4 h) increased, the
amount of FITC-dextran in the media in the lower
chambers also increased, indicating that Ang II dose-
dependently increased endothelial permeability in
HUVECs (Fig. S1a). TEER is another parameter for eval-
uating cell permeability and is negatively correlated with
cell permeability18. Ang II (500 nM) also signiﬁcantly
decreased TEER beginning at 4 h (Fig. S1b). Furthermore,
the adherens junction architecture and phosphorylation
state of VE-cadherin were examined to evaluate endo-
thelial permeability19,20; Ang II caused the disassembly of
VE-cadherin junctions (Fig. S2a) and Y731-speciﬁc
phosphorylation of VE-cadherin (Fig. S2b), indicating
disruption of adherens junctions. Taken together, these
data indicated that Ang II induced endothelial hyperper-
meability in a dose- and time-dependent manner in
HUVECs.
RAGE mediates Ang II-induced endothelial
hyperpermeability
To verify the involvement of RAGE signaling in Ang II-
induced endothelial hyperpermeability, siRNA speciﬁc for
RAGE (Fig. S3) was used to knock down RAGE-mediated
signaling. RAGE siRNA signiﬁcantly suppressed the Ang
II-induced upregulation of HMGB1, a major ligand for
RAGE known to be upregulated by Ang II21, at both the
mRNA (Fig. S4a) and protein (Fig. S4b) levels. During the
disassembly of VE-cadherin-mediated cell–cell contacts,
kinases such as p21-activated kinase (PAK), Src, and focal
adhesion kinase (FAK) facilitate C-tail phosphorylation of
VE-cadherin, which can lead to the dissociation of VE-
cadherin from its accessory molecule β-catenin22.
Since dephosphorylated β-catenin links cadherin to the
actin cytoskeleton and thereby contributes to endothelial
cell–cell junction stabilization23, phosphorylation of
β-catenin may indicate an increased risk of VE-cadherin
disassembly. According to our data, Ang II signiﬁcantly
increased the phosphorylation of Src, β-catenin, and VE-
cadherin, but this increase was signiﬁcantly attenuated by
RAGE siRNA (Fig. 1a). Furthermore, RAGE siRNA atte-
nuated the Ang II-induced disassembly of VE-cadherin
(Fig. 1b) and decreased the TEER values of conﬂuent
HUVEC monolayers (Fig. 1c). These results suggested
that RAGE activation modulates Ang II-induced VE-
cadherin disassembly and subsequent endothelial
hyperpermeability.
Activation of AT1R augments the RAGE signaling cascade
It has been reported that AT1R stimulation by Ang II
increases RAGE expression in diabetic atherosclerosis11,
suggesting possible crosstalk between AT1R-mediated
signaling and RAGE-mediated signaling. Additionally,
regarding RAGE signaling in endothelial hyperperme-
ability, mammalian diaphanous 1 (mDia1), a member of
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Fig. 1 (See legend on next page.)
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the diaphanous-related formin family, was recently iden-
tiﬁed as a new signaling molecule in AGE-induced
endothelial hyperpermeability. Mechanistically, mDia1
transduces signaling via binding to the cytoplasmic
domain of RAGE (ctRAGE)24,25.
In the present study, Ang II signiﬁcantly increased the
expression of AT1R, RAGE, and mDia1, but this increase
was signiﬁcantly attenuated by losartan, a well-known
selective, competitive AT1R antagonist26 (Fig. 1d). Fur-
thermore, Ang II-induced phosphorylation of Src,
β-catenin, and VE-cadherin was signiﬁcantly attenuated
by the AT1R antagonist (Fig. 1e). These data suggested
that the activation of AT1R reinforces RAGE signaling at
least partially by upregulating major mediators of RAGE
signaling such as RAGE itself and mDia1. Additionally,
the Ang II-induced increase in AT1R expression was
signiﬁcantly suppressed by RAGE siRNA at both the
mRNA and protein levels (Fig. 1f), suggesting that RAGE
may relay signals between AT1R activation and tran-
scription, establishing a transactivation circuit composed
of AT1R-mediated signaling and RAGE-mediated
signaling.
HMGB1 links AT1R-mediated signaling and RAGE-
mediated signaling
A well-known RAGE ligand, HMGB1, can be upregu-
lated by Ang II. In addition, our recent study demon-
strated that Ang II-induced HMGB1 secretion is critical
for the development of cardiac hypertrophy through
RAGE activation27. Therefore, it was hypothesized that
Ang II-induced AT1R activation increases
HMGB1 secretion and that HMGB1 subsequently binds
to RAGE, initiating RAGE-mediated signaling. In support
of this hypothesis, the amount of HMGB1 secreted into
the culture medium was signiﬁcantly increased by Ang II,
and this increase was inhibited by the AT1R antagonist
losartan (Fig. 2a). Furthermore, HMGB1 neutralizing
antibodies signiﬁcantly suppressed the Ang II-induced
expression of AT1R, RAGE, and mDia1 (Fig. 2b) as well as
phosphorylation of VE-cadherin at Y731 (Fig. 2c). These
data strongly suggested that HMGB1 is the link that
connects AT1R activation with the augmentation of
RAGE signaling and subsequent disassembly of VE-
cadherin.
NF-κB facilitates the key modulators of Ang II-induced
endothelial hyperpermeability
The aforementioned data indicated that Ang II aug-
ments RAGE signaling by increasing the expression of not
only RAGE but also mDia1, a critical accessory molecule
in the transduction of RAGE signals. To verify the
importance of mDia1 in Ang II-induced endothelial
hyperpermeability, mDia1-speciﬁc siRNA (Fig. S5) was
utilized. mDia1 siRNA signiﬁcantly attenuated Ang II-
induced phosphorylation of Src, β-catenin, and VE-
cadherin (Fig. 3a), demonstrating the importance of
mDia1 in Ang II-induced endothelial hyperpermeability.
To further investigate the regulatory mechanism of
mDia1, the effect of RAGE knockdown on mDia1
expression was examined, and the results indicated that
RAGE-mediated signaling is required for Ang II-induced
expression of mDia1 (Fig. 3b, c). Although the tran-
scriptional regulation of mDia1 remains to be clariﬁed,
the transcription of both AT1R and RAGE has been
reported to be mediated by the transcription factor NF-
κB28–31. Furthermore, RAGE activation can lead to NF-
κB-mediated expression of proinﬂammatory molecules,
including RAGE itself32. Therefore, the effect of CAPE, a
well-known NF-κB inhibitor (Fig. S6)33, on the expression
of AT1R, RAGE, and mDia1 was examined. Similar to
RAGE siRNA, CAPE signiﬁcantly attenuated Ang II-
induced expression of AT1R, RAGE, and mDia1 (Fig. 3d).
Furthermore, CAPE signiﬁcantly suppressed Ang II-
induced expression of HMGB1 (Fig. S7). Taken toge-
ther, these data indicated that NF-κB may be one of the
major transcription factors contributing to the transcrip-
tion of the key molecules involved in Ang II-induced
endothelial hyperpermeability.
(see ﬁgure on previous page)
Fig. 1 Importance of the AT1R-RAGE axis in Ang II-induced endothelial hyperpermeability in HUVECs. a Changes in the phosphorylation of
VE-cadherin (Y731), Src (Tyr416), and β-catenin (Ser552) in HUVECs following transfection with RAGE siRNA and treatment with Ang II. Expression
values were normalized to those of VE-cadherin, Src, and β-catenin (n= 4 for each lane). b Immunocytochemistry of VE-cadherin (green) and DAPI
(nuclei, blue), as examined under a confocal microscope (white scale bars: 50 μm in merged images and 20 μm in magniﬁed images; ×400
magniﬁcation). The main images were selected from representative regions. c HUVECs transfected with siRNA targeting RAGE or with scrambled
sequences were incubated for 72 h and were then stimulated with Ang II for 6 h. TEER was measured every 2 h. ***p < 0.001 vs. control, ###p < 0.001
vs. Ang II (n= 3 for each lane). d, e Protein expression in HUVECs treated with Ang II and losartan (10 μM) alone or in combination for 4 h, as
determined by western blotting. The relative values of AT1R, RAGE, and mDia1 expression values were normalized to that of GAPDH (n= 4 for each
lane). The relative values of phospho-Src, phospho-β-catenin, and phospho-VE-cadherin expression were normalized to those of Src, β-catenin, and
VE-cadherin, respectively (n= 3 for each lane). f Changes in AT1R protein levels in HUVECs following transfection with RAGE siRNA, as determined by
western blotting. Expression was normalized to that of GAPDH (top). Changes in AT1R mRNA expression in HUVECs following transfection with RAGE
siRNA, as determined by RT-PCR (bottom). Expression was normalized to that of the 18S rRNA gene (n= 4 for each lane). The values are presented as
the means ± SEMs. *p < 0.05; **p < 0.01; ***p < 0.001; ns not signiﬁcant by one-way analysis of variance (ANOVA) followed by Tukey’s multiple
comparisons test
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sRAGE attenuates Ang II-induced endothelial
hyperpermeability by disrupting the RAGE-mediated
signaling cascade
Although RAGE siRNAs signiﬁcantly attenuated Ang
II-induced endothelial hyperpermeability in vitro, the
unsolved issues with the use of siRNAs in vivo, such as
their low cellular uptake, off-target effects, and instability
in serum34, could be problematic if a RAGE signaling
inhibitor were to be developed as a clinical therapeutic
agent. Therefore, as an alternative to RAGE siRNA,
sRAGE, which can directly act on circulating RAGE
ligands such as HMGB1, was utilized to disrupt RAGE
signaling. According to our data, sRAGE signiﬁcantly
attenuated the Ang II-induced decrease in TEER in a
dose- and time-dependent manner (Fig. S8), suggesting
that it was effective in suppressing the induction of
endothelial hyperpermeability by Ang II.
When sRAGE was used alone at a concentration of
2 µg/ml, it did not signiﬁcantly affect the permeability of
the endothelial monolayer but signiﬁcantly attenuated the
Ang II-induced increase in the permeability of the endo-
thelial monolayer, as evidenced by the results of the
permeability assay using FITC-labeled dextran 40 (Fig. 4a)
and the TEER assay (Fig. 4b). The immunocytochemical
analysis results showed that sRAGE also prevented Ang
II-induced dissociation of VE-cadherin (Fig. 4c) and
Fig. 2 HMGB1 is an important mediator of AT1R-RAGE signaling. HUVECs were treated with Ang II in the absence or presence of losartan for 4 h.
a HMGB1 release in supernatants was measured by ELISA and western blotting (n= 4 for each lane). b, c HUVECs were incubated with Ang II in the
presence or absence of anti-HMGB1-neutralizing antibody (50 ng/ml) for 4 h and analyzed by western blotting. The relative values of AT1R, RAGE, and
mDia1 expression were normalized to that of GAPDH (n= 4 for each lane). The relative values of phospho-VE-cadherin expression were normalized
to that of VE-cadherin (n= 3 for each lane). The values are presented as the means ± SEMs. *p < 0.05; **p < 0.01; ***p < 0.001; ns not signiﬁcant by
one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test
Jeong et al. Experimental & Molecular Medicine (2019) 51:113 Page 7 of 15
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
Fig. 3 RAGE regulates Ang II-induced endothelial hyperpermeability via mDia1. a HUVECs were transfected with mDia1 siRNA and cultured in
the presence of Ang II for an additional 4 h. Western blot analysis was performed to observe changes in phospho-Src, phospho-β-catenin, and
phospho-VE-cadherin protein expression (n= 4 for each lane). b Changes in mDia1 protein levels in HUVECs following transfection with RAGE siRNA,
as determined by western blotting. Expression was normalized to that of GAPDH (n= 3 for each lane). c Changes in mDia1 mRNA expression in
HUVECs following transfection with RAGE siRNA, as determined by RT-PCR. Expression was normalized to that of the 18S rRNA gene (n= 4 for each
lane). d HUVECs were treated with Ang II and the NF-κB inhibitor (5 μg/ml) alone or in combination for 4 h. Protein levels of AT1R, RAGE, and mDia1
in cell lysates were determined by western blotting. Expression was normalized to that of GAPDH (n= 4 for each lane). The values are presented as
the means ± SEMs. *p < 0.05; **p < 0.01; ***p < 0.001; ns not signiﬁcant by one-way analysis of variance (ANOVA) followed by Tukey’s multiple
comparisons test
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Fig. 4 Soluble RAGE (sRAGE) attenuates Ang II-induced endothelial hyperpermeability. a HUVECs were treated with sRAGE (2 μg/ml) for 1 h
and were then subjected to Ang II treatment for 4 h. Endothelial permeability was assessed in media from the lower chambers after the addition of
FITC-dextran 40 to the upper chambers for 1 h (n= 3 for each lane). b TEER was measured every 2 h. *p < 0.05 vs. control, #p < 0.05 vs. Ang II (n= 3
for each lane). c Immunocytochemistry of VE-cadherin (green) and DAPI (nuclei, blue) was performed, and samples were directly examined under a
confocal microscope (white scale bars: 50 μm in merged images and 5 μm in magniﬁed images; ×400 magniﬁcation). The main images were selected
from representative regions. d HUVEC extracts were analyzed by western blotting to assess phospho-Src, phospho-β-catenin, and phospho-VE-
cadherin expression. Expression values were normalized to those of Src, β-catenin, and VE-cadherin (n= 4 for each lane). e The protein levels of AT1R,
RAGE, and mDia1 were determined by western blotting. Expression was normalized to that of GAPDH (n= 3 for each lane). f HMGB1 release in
supernatants was measured by ELISA and western blotting (n= 3 for each lane). The values are presented as the means ± SEMs. *p < 0.05; **p < 0.01;
***p < 0.001; ns not signiﬁcant by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test
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phosphorylation of Src, β-catenin, and VE-cadherin
(Fig. 4d). Furthermore, Ang II-induced upregulation of
AT1R, RAGE, and mDia1 was signiﬁcantly attenuated by
sRAGE at both the mRNA level (Fig. S9) and the protein
level (Fig. 4e). The amount of HMGB1 secreted following
Ang II stimulation was also decreased by sRAGE treat-
ment (Fig. 4f), possibly due to the suppression of Ang II-
induced HMGB1 mRNA synthesis (Fig. S10). These
results indicated that the effect of sRAGE was comparable
to that of RAGE siRNA in terms of both disrupting the
RAGE-mediated signaling cascade and preventing Ang II-
induced endothelial hyperpermeability in vitro.
In vivo delivery of sRAGE attenuates Ang II-induced
endothelial hyperpermeability of the aorta in ApoE KO
mice
The Evans blue leakage assay is a well-accepted method
for evaluating vascular permeability35. As shown in Fig. 5a,
vascular permeability was prominently increased by Ang II
infusion compared to that in the control group, whereas
in vivo delivery of sRAGE dramatically attenuated Ang II-
induced vascular hyperpermeability. This ﬁnding was
quantitatively conﬁrmed by calculating both the Evans
blue-positive area with respect to the total area (Fig. 5b)
and the total amount of Evans blue per gram of tissue (Fig.
5c). Closer examination of the endothelium using TEM
demonstrated that Ang II infusion caused widening of the
intercellular space, which was prevented by in vivo sRAGE
delivery (Fig. 5d). Taken together, these results indicated
that in vivo delivery of sRAGE effectively suppressed Ang
II-induced vascular hyperpermeability in vivo.
Discussion
Previous studies have demonstrated that both Ang II
signaling and RAGE-mediated signaling play important
roles in the development of endothelial hyperperme-
ability15,36. Although the importance of crosstalk between
signaling through AT1R and RAGE in the pathogenesis of
diabetic atherosclerosis has been reported11, to our
knowledge, such crosstalk between these two signaling
pathways in the mediation of endothelial hyperperme-
ability has not been experimentally conﬁrmed. In the
present study, we provided empirical evidence that these
two pathways are linked by demonstrating that Ang II
increased the production of HMGB1, one of the major
ligands for RAGE, in an NF-κB-dependent manner (Fig.
2a, Fig. S7) and that the neutralization of secreted
HMGB1 using either HMGB1-speciﬁc antibodies (Fig. 2b,
c) or sRAGE, a decoy receptor for HMGB1 (Figs. 4 and 5),
signiﬁcantly attenuated Ang II-induced endothelial
hyperpermeability. Thus, the present study is the ﬁrst to
report the existence of HMGB1-mediated crosstalk
between Ang II signaling and RAGE-mediated signaling
in endothelial hyperpermeability.
One of the important physiological functions of the
vascular endothelium is to regulate exchange between the
blood and interstitial ﬂuid, and meticulous regulation of
endothelial permeability is critical for the maintenance of
circulatory homeostasis2, considering that endothelial
dysfunction or endothelial hyperpermeability can
exacerbate a variety of diseases, including but not limited
to cardiovascular diseases and tumor metastasis37,38. To
date, several mechanisms of endothelial permeability
regulation have been proposed, and Ang II is one of the
well-established agents that causes endothelial hyperper-
meability39–41. Consistent with these previous results,
Ang II signiﬁcantly induced endothelial hyperperme-
ability, demonstrating the disruption of endothelial cell
adherens junctions, a common characteristic of endo-
thelial hyperpermeability (Fig. S2).
VE-cadherin is a component of endothelial adherens
junctions that plays a major role in the maintenance of
endothelial cell–cell contact by interacting with the
cytoskeleton via anchoring molecules such as
β-catenin19,42, and its physiological regulation is compro-
mised in Ang II-induced endothelial dysfunction43,44. The
cytoplasmic tail of VE-cadherin contains at least ﬁve tyr-
osine residues (Y648, Y658, Y685, Y731, and Y733), and
phosphorylation of Y731 mediated by the cytoplasmic
protein tyrosine kinase Src is especially important in
modulating VE-cadherin activity, since C-tail phosphor-
ylation of VE-cadherin can lead to the dissociation of VE-
cadherin from its accessory molecule β-catenin22,45. Fur-
thermore, dephosphorylated β-catenin stabilizes endothe-
lial cell–cell junctions by linking cadherin to the actin
cytoskeleton23; therefore, phosphorylation of β-catenin
may indicate an increased risk of VE-cadherin disassembly
and subsequent endothelial hyperpermeability46,47.
In the present study, by demonstrating that knockdown of
RAGE via siRNA effectively suppressed Ang II-induced
phosphorylation of Src, β-catenin, and VE-cadherin (Fig. 1a)
as well as the disruption of adherens junctions (Fig. 1b) and
the decrease in TEER (Fig. 1c), we proved that the RAGE-
mediated signaling cascade contributes signiﬁcantly to Ang
II-induced endothelial hyperpermeability. It has been
reported that RAGE-mediated signal transduction requires
interaction of the RAGE cytoplasmic domain with the FH1
domain of the formin mDia1 (refs. 25,48). Furthermore,
according to our data, RAGE not only requires mDia1 to
transmit the signal downstream (Fig. 3a) but also positively
regulates the expression of mDia1 in an NF-κB-dependent
manner (Fig. 3d), suggesting a positive feedback loop
between RAGE and mDia1 to augment the RAGE-mediated
signaling cascade. In fact, since the NF-κB inhibitor also
attenuated Ang II-induced expression of AT1R and RAGE
(Fig. 3d), it was speculated that NF-κB was a key molecule
facilitating an extended positive feedback network involving
AT1R, RAGE, and mDia1 in Ang II-induced endothelial
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hyperpermeability. Previous studies demonstrating RAGE-
mediated activation of NF-κB27,49 and NF-κB-dependent
upregulation of AT1R28,31 and RAGE29,30 also support this
speculation. However, without direct empirical evidence,
this speculation has to remain a hypothesis yet to be tested,
and this insufﬁciency is one of the limitations of the
present study.
Assuming that NF-κB is the key intracellular mediator
of Ang II-induced endothelial hyperpermeability,
HMGB1 seems to be the critical link that connects AT1R-
mediated signaling and RAGE-mediated signaling in the
present study. Although HMGB1 is a nonhistone nuclear
protein primarily localized in the nucleus50, it can be actively
released into the extracellular space upon exposure to
inﬂammatory stimuli such as TNF-α51. Additionally—and
more closely related to the present study—Ang II-induced
upregulation of HMGB1 has also been reported27,52. These
previous observations agree well with our data that clearly
demonstrated AT1R-mediated upregulation of HMGB1
(Fig. 2a). Furthermore, yet another previous study reported
HMGB1-induced endothelial hyperpermeability53,54, and our
data demonstrating the effect of the HMGB1-neutralizing
antibody on suppressing the upregulation of key molecules
(Fig. 2a) and VE-cadherin phosphorylation (Fig. 2c) strongly
support the idea that HMGB1 is the critical link in Ang II-
induced endothelial hyperpermeability. However, the
observation that both RAGE siRNA (Fig. S4) and the NF-κB
inhibitor (Fig. S7) signiﬁcantly suppressed Ang II-induced
upregulation of HMGB1 strongly implies that Ang II-
induced upregulation of HMGB1 was achieved not only by
AT1R activation but also by RAGE activation. Multiple steps
or multiple mechanisms encompassing both AT1R activa-
tion and RAGE activation might have been acting to gen-
erate the Ang II-induced upregulation of HMGB1 observed
in the present study. Based on the acquired data, the fol-
lowing stepwise signaling events are speculated to occur.
Fig. 5 Effects of sRAGE on Ang II-induced endothelial hyperpermeability in vivo. Twelve-week-old ApoE KO mice were used to investigate
endothelial hyperpermeability. Ang II was injected into mice with or without sRAGE for 6 weeks. Then, Evans blue (EB) dye in saline was administered
via the jugular vein. a Representative photographs of aortas stained with Evans blue in ApoE KO mice. b Quantiﬁcation of positive areas of Evans blue
staining in the aortas, as estimated using ImageJ. c Evans blue dye was eluted from the aortas by incubation with formamide. The amount of dye was
quantiﬁed by spectrophotometry at 610 nm. d Representative TEM images of the EC junction area (original magniﬁcation, ×30,000). EL elastic lamina,
EC endothelial cell; scale bar, 1000 nm. Control group, n= 10; Ang II group, n= 13; Ang II+ sRAGE group, n= 11; sRAGE group, n= 7. The results are
representative of at least four separate experiments. The values are presented as the means ± SEMs. *p < 0.05; **p < 0.01; ***p < 0.001; ns not
signiﬁcant by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test
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First, Ang II activates AT1R, which subsequently
activates NF-κB. Activated NF-κB then increases the
expression of HMGB1 along with that of AT1R, RAGE,
and mDia1. The increased HMGB1 is then released into
the extracellular space to activate RAGE. Finally, acti-
vated RAGE subsequently reactivates NF-κB to further
increase HMGB1 expression. In this scenario, Ang II can
directly increase the expression of HMGB1 by activating
Fig. 6 Schematic diagram of signal transduction pathways involved in Ang II-induced endothelial hyperpermeability via AT1R/RAGE/
mDia1/Src/β-catenin/VE-cadherin. a As Ang II binds to and stimulates AT1R, the expression and secretion of HMGB1 can be increased by NF-κB
activation. NF-κB-mediated expression of proinﬂammatory molecules, including RAGE itself, can occur. HMGB1 binds to RAGE, which can induce
RAGE-mediated activation of Src/β-catenin/VE-cadherin via mDia1. b Blockade of RAGE activation by sRAGE attenuates the Ang II-induced increase in
endothelial hyperpermeability by inhibiting RAGE-mediated signaling pathways
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NF-κB at the early stage (step 1 in Fig. 6) and indirectly
increase the expression of HMGB1 later by activating
RAGE (step 4 in Fig. 6). Therefore, blocking RAGE sig-
naling via siRNA or NF-κB inhibition could at least
partially suppress Ang II-induced upregulation of
HMGB1. Additionally, Ang II-induced hyperacetylation
of HMGB1 might cooperate with the above mechanism
to enhance the release of HMGB1 following Ang II sti-
mulation55. However, these proposed mechanisms were
not examined in detail in the present study, another
major limitation of this study. A systematic elucidation
of the underlying mechanisms, including the NF-κB-
dependent upregulation of key molecules mentioned
above, would make a very interesting subject for further
studies.
As our data demonstrate, knockdown of the RAGE
signaling cascade using RAGE-speciﬁc siRNA effectively
attenuated Ang II-induced endothelial hyperperme-
ability in vitro (Fig. 1a–c). However, there is concern
about using siRNAs in in vivo studies, although using
siRNA in vivo would have been ideal for the present
study. In contrast to in vitro experiments in which most
variables are controllable, in vivo conditions are difﬁcult
to control due to the excessive number of uncontrol-
lable variables. Furthermore, especially for siRNA-
mediated knockdown in vivo, unsolved issues such as
the low cellular uptake, off-target effects, and instability
in serum still exist34. By using RAGE knockout ani-
mals14 instead of siRNA-mediated knockdown, these
limitations could have been avoided. However, unfor-
tunately, this animal model exceeded the budget; thus,
sRAGE was utilized as the second-best option in the
present study. Since sRAGE is expected to act on cir-
culating RAGE ligands such as HMGB1, delivering
sRAGE via IP injection was thought to be a much more
reliable approach than RAGE knockdown using siRNA,
which has to ﬁrst enter endothelial cells to exert the
expected effect. Thus, if a RAGE signaling inhibitor
were to be developed as a clinical therapeutic agent,
delivering peptides would be more effective than deli-
vering siRNA. Additionally, since the main aim of the
present study was to suppress RAGE-mediated signaling
rather than the expression of RAGE itself, we believe
that using sRAGE rather than siRNA sufﬁciently serves
the purpose and is well justiﬁed.
sRAGE is a matrix metalloproteinase-cleaved form of
RAGE released from the cell surface that functions as
an extracellular decoy for RAGE ligands; sRAGE has
been implicated in chronic diseases and suggested to be
a therapeutically useful biomarker for diseases invol-
ving the activation of RAGE signaling cascades56,57. The
therapeutic potential of sRAGE has been demonstrated
in various in vivo disease models, including models of
vascular inﬂammation, diabetes, retinal vascular/neu-
ronal dysfunction, and cardiomyocyte hyper-
trophy27,58,59. However, to our knowledge, its
therapeutic potential in Ang II-induced endothelial
hyperpermeability has not been empirically examined.
Therefore, the present study is the ﬁrst to investigate
the therapeutic potential of sRAGE in the prevention of
endothelial hyperpermeability. According to our data,
sRAGE effectively attenuated Ang II-induced endothe-
lial permeability in vitro (Fig. 4). Additionally, in the
in vivo study using Ang II-infused atherosclerosis-
prone apolipoprotein E knockout mice, sRAGE sig-
niﬁcantly decreased the Evans blue-positive areas
compared to those in the Ang II-infused or the saline-
infused group, effectively maintaining the integrity of
cell–cell contacts (Fig. 5).
The present study provided strong evidence for
HMGB1-mediated crosstalk between AT1R-mediated
signaling cascades and RAGE-mediated signaling cas-
cades in Ang II-induced endothelial hyperpermeability
(Fig. 6). In the clinical context, the results of this study
indicate that disrupting the crosstalk between AT1R sig-
naling and RAGE signaling can be an effective means to
control Ang II-induced endothelial dysfunction and that
sRAGE-mediated blockade of RAGE signaling has sig-
niﬁcant therapeutic potential. To fully address the unan-
swered issues, further studies are warranted.
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